Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer
Autore:
Koukourakis, MI; Giatromanolaki, A; Thorpe, PE; Brekken, RA; Sivridis, E; Kakolyris, S; Georgoulias, V; Gatter, KC; Harris, AL;
Indirizzi:
Univ Hosp Iraklion, Dept Radiotherapy Oncol, Tumour & Angiogenesis Res Grp, Iraklion 71110, Crete, Greece Univ Hosp Iraklion Iraklion Crete Greece 71110 klion 71110, Crete, Greece Univ Hosp Iraklion, Canc Biol Lab, Iraklion 71110, Crete, Greece Univ HospIraklion Iraklion Crete Greece 71110 klion 71110, Crete, Greece Democritus Univ Thrace, Dept Pathol, Alexandroupolis 68100, Greece Democritus Univ Thrace Alexandroupolis Greece 68100 upolis 68100, Greece Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 Ctr, Dept Pharmacol, Dallas, TX 75235 USA Oxford Radcliffe Hosp, Dept Imperial Canc Res Fund, Med Oncol Unit, OxfordOX3 7LJ, England Oxford Radcliffe Hosp Oxford England OX3 7LJ nit, OxfordOX3 7LJ, England Oxford Radcliffe Hosp, Dept Cellular Sci, Oxford OX3 7LJ, England Oxford Radcliffe Hosp Oxford England OX3 7LJ ci, Oxford OX3 7LJ, England
Titolo Testata:
CANCER RESEARCH
fascicolo: 11, volume: 60, anno: 2000,
pagine: 3088 - 3095
SICI:
0008-5472(20000601)60:11<3088:VEGFAM>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERMEABILITY FACTOR; IN-VITRO; SYNOVIAL FIBROBLASTS; TUMOR ENDOTHELIUM; BREAST-CANCER; RECEPTOR KDR; ANGIOGENESIS; EXPRESSION; CARCINOMA; SURVIVAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Koukourakis, MI Tumour & Angiogenesis Res Grp, 18 Dimokratias Ave, Iraklion 71306, Crete, Greece Tumour & Angiogenesis Res Grp 18 Dimokratias Ave Iraklion Crete Greece 71306
Citazione:
M.I. Koukourakis et al., "Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer", CANCER RES, 60(11), 2000, pp. 3088-3095

Abstract

Vascular endothelial growth factor (VEGF) is an important angiogenic factor, linked to poor outcome in human malignancies including non-small cell lung carcinoma (NSCLC). We used the 11B5 monoclonal antibody recognizing the VEGF/KDR complex (R. A. Brekken et al., Cancer Res., 58: 1952-1959, 1998) to assess the VEGF expression in cancer cells and the VEGF/KDR activated microvessel density (aMVD) in early operable NSCLC. The JC70 anti-CD31 monoclonal antibody was used to assess the standard MVD (sMVD). The aMVD was significantly higher in the invading front of the tumors and in the normal lung adjacent to the tumors as compared with normal lung distant to the tumor orto inner tumor areas (P < 0.0002). The sMVD was higher in the normal lung and decreased from the invading front to inner tumor areas (P < 0.0001). However, the vascular activation (aMVD:sMVD) was 4-6 times higher in the tumor areas as compared with lung from normal individuals (36-58% versus 9%; P < 0.0001). Fibroblast 11B5 reactivity, noted in 25% of cases, correlated with high aMVD and sMVD in the inner tumor areas. Multivariate analysis showed that aMVD was the most potent and independent prognostic factor (P = 0.001; t-ratio, 3.28). It is concluded that intense VEGF/KDR angiogenic pathwayactivation is a tumor-specific feature in more than 50% of NSCLC cases andis associated with poor postoperative outcome. Clinical trials involving targeting of the VEGF/KDR-positive vasculature with specific antibodies, such as 11B5, are, therefore, encouraged.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 15:40:12